Noteworthy - Pharmaceutical Executive

ADVERTISEMENT

Noteworthy

Pharm Exec: Annual Press Audit 2014

March 3, 2014

Pharm Exec's latest survey of press issues shows that media coverage continues to remain on balance negative toward the industry, by a slight margin: 47% this year compared to a 46% average over the last seven years.

The Push for Transparency: Risks, Costs, and Concerns

February 26, 2014

The growing clamor for broader access to information on health care practices, policies and costs is affecting research, marketing and compliance, writes Jill Wechsler.

What Would Britain's EU Exit Mean for Drugmakers?

February 25, 2014

The possibility of a future "Brexit" — a British exit from the EU — has been exercising the world of medicines, writes Peter O'Donnell.

Pharm Exec Global Digest — Sales & Marketing Special

February 12, 2014

In the latest issue of PEGD: Face-to-Face Meetings in the Digital Age; the US Rx Rep in the Obamacare Era; the Future of the iPad — And more

Innovation and Market Growth in Brazil

February 10, 2014

Brazil is the first Latin American country to emerge as a global biopharmaceutical collaborator. Hellen Berger reports.

Pharm Exec's Emerging Pharma Leaders 2014 — Nominate Now

February 7, 2014

It's time for you to tell us who you think should receive Pharm Exec's 2014 Emerging Pharma Leadership Award. Read more for details of how to nominate a colleague — or yourself.

Growing Pains: The European Medicines Agency at 20

February 3, 2014

Reflector looks at the growing pains of the European Medicine Agency (EMA) as it faces the key policy challenges of 2014.

Takeda's Oncology Taskmaster

February 1, 2014

Millennium Takeda's new president, Anna Protopapas, explains the life choices that brought her from Cyprus to Cambridge—and a lead position in the hotly contested search to make cancer a treatable disease.

The Active Patient: Faces Of Change

February 1, 2014

Advocacy organizations and individual patients are getting more involved in every facet of the healthcare system, from drug R&D, to federal and state policy all fueled by the hour-to-hour passion of living with a disease.

ADVERTISEMENT

Click here